Literature DB >> 16820098

Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract.

Gretchen E Garcia1, Arevalo Nicole, Shylesh Bhaskaran, Ashima Gupta, Natasha Kyprianou, Addanki P Kumar.   

Abstract

Evidence from epidemiological studies suggests that plant-based diets can reduce the risk of prostate cancer. However, very little information is available concerning the use of botanicals in preventing prostate cancer. As a first step toward developing botanicals as prostate cancer preventives, we examined the effect of Nexrutine on human prostate cancer cells. Nexrutine is a herbal extract developed from Phellodendron amurense. Phellodendron extracts have been used traditionally in Chinese medicine for hundreds of years as an antidiarrheal, astringent, and anti-inflammatory agent. The present study investigated its potential antitumor effect on human prostate cancer cells. Our results suggest that it inhibits tumor cell proliferation through apoptosis induction and inhibition of cell survival signaling. The results of the present study indicate that Nexrutine treatment 1) inhibits the proliferation of both androgen-responsive and androgen-independent human prostate cancer cells through induction of apoptosis; 2) reduces levels of pAkt, phosphorylated cAMP response-binding protein (pCREB) and CREB DNA-binding activity; and 3) induces apoptosis in prostate cancer cells stably overexpressing Bcl-2. Further, Akt kinase activity was reduced in cells treated with Nexrutine, and ectopic expression of myristoylated Akt protected from Nexrutine induced inhibition of proliferation, implicating a role for Akt signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820098      PMCID: PMC1601469          DOI: 10.1593/neo.05745

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  38 in total

Review 1.  Cellular survival: a play in three Akts.

Authors:  S R Datta; A Brunet; M E Greenberg
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

2.  Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN.

Authors:  N Nakamura; S Ramaswamy; F Vazquez; S Signoretti; M Loda; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

Review 3.  Transcriptional regulation by the phosphorylation-dependent factor CREB.

Authors:  B Mayr; M Montminy
Journal:  Nat Rev Mol Cell Biol       Date:  2001-08       Impact factor: 94.444

Review 4.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

5.  PC-SPES--a lesson for future dietary supplement research.

Authors:  Jeffrey White
Journal:  J Natl Cancer Inst       Date:  2002-09-04       Impact factor: 13.506

6.  2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells.

Authors:  A P Kumar; G E Garcia; T J Slaga
Journal:  Mol Carcinog       Date:  2001-07       Impact factor: 4.784

Review 7.  Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer.

Authors:  Hiroshi Miyamoto; Saleh Altuwaijri; Yi Cai; Edward M Messing; Chawnshang Chang
Journal:  Mol Carcinog       Date:  2005-09       Impact factor: 4.784

8.  Topical anti-inflammatory activity of some Asian medicinal plants used in dermatological disorders.

Authors:  M J Cuéllar; R M Giner; M C Recio; S Máñez; J L Ríos
Journal:  Fitoterapia       Date:  2001-03       Impact factor: 2.882

9.  Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study.

Authors:  L N Kolonel; J H Hankin; A S Whittemore; A H Wu; R P Gallagher; L R Wilkens; E M John; G R Howe; D M Dreon; D W West; R S Paffenbarger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-08       Impact factor: 4.254

10.  The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.

Authors:  A L Hsu; T T Ching; D S Wang; X Song; V M Rangnekar; C S Chen
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

View more
  28 in total

1.  Resveratrol targets transforming growth factor-β2 signaling to block UV-induced tumor progression.

Authors:  Kwang Ho Kim; Jung Ho Back; Yucui Zhu; Josh Arbesman; Mohammad Athar; Levy Kopelovich; Arianna L Kim; David R Bickers
Journal:  J Invest Dermatol       Date:  2010-08-19       Impact factor: 8.551

2.  Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.

Authors:  Xuehong Deng; Han Liu; Jiaoti Huang; Liang Cheng; Evan T Keller; Sarah J Parsons; Chang-Deng Hu
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

3.  A system for screening agonists targeting beta2-adrenoceptor from Chinese medicinal herbs.

Authors:  Hui Wang; Shi-you Li; Chuan-ke Zhao; Xin Zeng
Journal:  J Zhejiang Univ Sci B       Date:  2009-04       Impact factor: 3.066

4.  Palmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP.

Authors:  Heather G Hambright; Izhar Singh Batth; Jianping Xie; Rita Ghosh; Addanki Pratap Kumar
Journal:  Mol Carcinog       Date:  2014-07-07       Impact factor: 4.784

5.  Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer.

Authors:  Jingjing Gong; Jianping Xie; Roble Bedolla; Paul Rivas; Divya Chakravarthy; James W Freeman; Robert Reddick; Scott Kopetz; Amanda Peterson; Huamin Wang; Susan M Fischer; Addanki P Kumar
Journal:  Clin Cancer Res       Date:  2014-02-11       Impact factor: 12.531

6.  Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.

Authors:  Addanki P Kumar; Shylesh Bhaskaran; Manonmani Ganapathy; Katherine Crosby; Michael D Davis; Peter Kochunov; John Schoolfield; I-Tien Yeh; Dean A Troyer; Rita Ghosh
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

7.  Genomic organization, alternative splicing and tissues expression of porcine CREB3L4 gene.

Authors:  Y M Qi; T Lei; L Zhou; X D Chen; Q Q Long; H Long; D Jin; L Gan; Z Q Yang
Journal:  Mol Biol Rep       Date:  2008-11-04       Impact factor: 2.316

8.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

9.  Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells.

Authors:  Jingjing Gong; Amanda R Muñoz; Subramanya Pingali; Florastina Payton-Stewart; Daniel E Chan; James W Freeman; Rita Ghosh; Addanki P Kumar
Journal:  Mol Carcinog       Date:  2016-05-25       Impact factor: 4.784

10.  Regulation of Cox-2 by cyclic AMP response element binding protein in prostate cancer: potential role for nexrutine.

Authors:  Rita Ghosh; Gretchen E Garcia; Katherine Crosby; Hiroyasu Inoue; Ian M Thompson; Dean A Troyer; Addanki P Kumar
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.